Medscape Live is bringing back-to-back educational programs to San Diego next month focused on indolent systemic mastocytosis, or ISM.

Detailed results from bezuclastinib’s positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic ...

Cogent Biosciences, Inc. (($COGT)) announced an update on their ongoing clinical study. Cogent Biosciences, Inc. is conducting a Phase 2 clinical ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH) today highlighted FDA Orphan Drug Designation for HT-KIT and new preclinical data demonstrating >80% suppression of KIT expression and significant tumor-volume ...

Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this ...

Hoth Therapeutics (HOTH) highlighted FDA Orphan Drug Designation for HT-KIT and new preclinical data demonstrating greater than80% suppression of ...

Sanofi posted strong Q3 results amid currency challenges; discover key pipeline updates and growth prospects for investors.

Investing.com -- Cogent Biosciences Inc (NASDAQ:COGT) stock surged 8.3% in Monday’s premarket trading after the company announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough ...

Q3 2025 Earnings Call October 24, 2025 8:30 AM EDTCompany ParticipantsThomas Larsen - Head of Investor RelationsPaul Hudson - CEO ...

Mast cell activation disorders (MCAD) encompass a wide range of immune-mediated conditions characterized by episodic or chronic mast cell activation, ...

For me, there are two main takeaways from the study. The first is that we still don't take CSU seriously enough. It is a ...